Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 10Pancreatic Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 7Neoplasm Metastasis 4Colorectal Cancer Metastatic 4Stomach Neoplasms 3Ovarian Neoplasms 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Gallbladder Neoplasms 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2Zollinger-Ellison Syndrome 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Somatostatinoma 1Sarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Gemcitabine 2Taxes 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Gene Expression Profiling 1Docetaxel 1Cisplatin 1Capecitabine 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Unknown Primary × Capecitabine × Clear all
NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡